Primary central nervous system lymphoma in daily practice and the role of autologous stem cell transplantation in relapsed disease: A retrospective multicenter study

Transfus Apher Sci. 2016 Feb;54(1):80-4. doi: 10.1016/j.transci.2016.01.018. Epub 2016 Jan 12.


We investigated the course of 54 patients presenting with primary central nervous system lymphoma, who were treated in daily practice. The patients were treated with chemotherapy and/or radiotherapy and/or intrathecal chemotherapy. At a median follow-up period of 23 months (range 1-71), median relapse-free survival (RFS) and overall survival (OS) were not reached. Estimated 2-year RFS and OS rates were 42% and 48%, respectively. Ten relapsed PCNSL patients underwent ASCT. Complete remission rate of these patients was 40%, with 20% treatment-related mortality. Estimated 2-year RFS and OS rates were 37% and 40%, respectively. The prognosis of patients with PCNSL, who received off-study treatment, is still dismal.

Keywords: Autologous stem cell transplantation; CNS lymphoma; High-dose chemotherapy; Methotrexate; PCNSL.

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Central Nervous System Neoplasms / therapy*
  • Demography
  • Humans
  • Lymphoma / therapy*
  • Middle Aged
  • Practice Patterns, Physicians'*
  • Recurrence
  • Retrospective Studies
  • Stem Cell Transplantation*
  • Transplantation, Autologous
  • Young Adult